GlassScriptPhysician profile
James Albert Ross
NPI 1831190594
$888.37
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $88.10 · 2021: $225 · 2022: $15.34 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| Astellas Pharma US INC | $126.04 | 2019-2021 | |
| Boston Scientific Corporation | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $72.18 | 2019 | |
| Novo Nordisk INC | $55.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.14 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $39.98 | 2020-2021 | |
| Pfizer INC. | $35.26 | 2019 | |
| Glaxosmithkline, LLC. | $32.23 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $30.13 | 2020-2021 | |
| Lilly USA, LLC | $30.08 | 2021-2022 | |
| Sanofi Pasteur INC. | $27.47 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.63 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.58 | 2021 | |
| Allergan, INC. | $13.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.88 | 2019 | |
| Amarin Pharma, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.